INTRODUCTION
We previously reported 16 patients whose disease manifestation was a hitherto unrecognized clinical entity characterized by chronic bilateral lymphadenopathy as a result of rapidly growing mycobacteria (RGM) (1) . We later reported 129 cases of disseminated nontuberculous mycobacterial (NTM) infection-both RGM and slowly growing mycobacteria-in non-HIV infected patients from Thailand (2) . These patients had coinfection with other intracellular pathogens, including Cryptococcus neoformans, Histoplasma capsulatum, Talaromyces marneffei, disseminated salmonellosis; or severe varicella zoster virus infection (2) . Recently, we enrolled our patients with disseminated NTM infection into a study of adult onset immunodeficiency in Thailand and Taiwan. Most of the patients (88z) tested positive for anti-interferon-gamma autoantibodies (IFN-g Ab). Ninety-six percent of patients with IFN-g Ab have multiple opportunistic infections (3) . The presence of IFN-g Ab alters the IFN-g-interleukin (IL)-12 axis which is critical for the control of mycobacteria and other intracellular opportunistic pathogens (4) .
Cryptococcosis is an important opportunistic fungal infection; especially in human immunodeficiency virus (HIV) infected patients (5), organ transplant recipients, immunocompromised patients, and even among those who are phenotypically normal (6) . The clinical characteristics of cryptococcosis among HIV-infected and non-HIV-infected patients have been compared (7) (8) (9) . Central nervous system (CNS) involvement, especially meningitis, occurs more frequently in HIV-positive patients, whereas pulmonary involvement is more frequently observed in HIV-negative patients. Positive testing for the serum cryptococcal antigen is more common in HIV-positive patients with a higher antibody titer (6) (7) (8) . The main reason for the difference in clinical manifestation was the profound immunodeficiency in HIV-infected patients due to a low CD4 cell count. There has been no comparison of the clinical manifestation of cryptococcosis between patients with IFN-g Ab and HIV-infected patients. Information regarding differences in the clinical manifestations and laboratory diagnosis between these 2 populations may be useful for their recognition, diagnosis, and management in clinical practice. We herein compare the clinical manifestations of cryptococcosis between (i) non-HIVinfected patients with disseminated NTM infection who are likely to test positive for IFN-g Ab; and (ii) HIVinfected patients.
MATERIALS AND METHODS

Participants:
We conducted a retrospective, matched case-control study between January 1992 and December 2013 at Srinagarind Hospital, a 1,500-bed, tertiarycare hospital in northeastern Thailand. We reviewed the medical records of adult patients (＞15 years old) The Khon Kaen University Ethics Committee approved the study.
Laboratory investigations: anti-IFN-g detection using neutralizing enzyme-linked immune-solvent assay (ELISA): We modified the protocol for anti-IFN-g detection from that of Chi et al. (10) . Briefly, polystyrene plates (Maxisorp; Nunc, Roskilde, Denmark) were precoated with anti-IFN-g coating antibody (BD Biosciences, Franklin Lakes, NJ, USA). Patient serum was pre-incubated with 300 pg/ml of recombinant IFNg (BD Biosciences) at 379 C for 1 h before the addition of diluted plasma onto the precoated plates, which were then incubated for 2 h at room temperature. Plates were washed and a biotinylated anti-IFN-g antibody with horse radish peroxydase (HRP)-streptavidin (BD Biosciences) was added. Neutralization of IFN-g by antibodies in the patient serum was detected using the addition of HRP substrate (BD Biosciences). The results were calculated to give the percentage inhibition.
Any serum sample having a zinhibition ＞50z at a dilution of 1:5,000 was defined as reactive. At the time of sample collection, no patients were taking any immunosuppressive medication. We also performed the anti-IFN-g assay in 5 healthy control participants.
Statistical analysis: SPSS ver. 17 for Windows (SPSS, Chicago, IL, USA) was used for all analyses. Comparison of the continuous variables was analyzed using the Student's t-test or Mann-Whitney U test, as appropriate. Categorical data were analyzed using the Pearson's chi-square or the Fisher's exact test, as appropriate. A p-value ＜0.05 was considered statistically significant.
RESULTS
Over 21 years (1992 to 2013), we identified 16 patients who were HIV-negative with NTM infection and co-infected with cryptococcosis. Among these patients, there were 10 with sera available for testing, and they all tested positive for IFN-g Ab. We matched 32 cases of HIV-infected patients with cryptococcosis as the control group. A comparison of demographic data of cryptococcosis between the case and control groups is shown in Table 1 . Patients in the case group were significantly older than those in the control group (median age 44 vs. 32 years; p ＝ 0.04). Three cases (19z) had underlying diabetes mellitus, and 1 was receiving prednisolone for Sweet's syndrome. Patients in the case group were also more likely to have salmonellosis compared to those in the control group (25z vs. 0z; p ＝ 0.009). Besides NTM and cryptococcosis, case group patients were also co-infected with other opportunistic infections, including salmonellosis (n ＝ 4), herpes zoster (n ＝ 4), melioidosis (n ＝ 2), penicilliosis (n ＝ 1), tuberculosis (n ＝ 1), nocardiosis (n ＝ 1), and streptococcus group B (n ＝ 1). Among the 32 HIV-infected patients, 16 had previous opportunistic infections, the most common being herpes zoster (n ＝ 6), tuberculosis (n ＝ 4), and Pneumocystis jirovecii pneumonia (PCP; n ＝ 4).
The clinical features and laboratory diagnoses of cryptococcosis in the case and control groups are shown in Table 2 . Compared to those in control group, patients in the case group had a longer duration of illness from symptom onset until diagnosis (median 30 vs. 8.5 days; p ＜ 0.0001), were less likely to involve cryptococcal meningitis (19z vs. 97z; p ＜ 0.0001), and were more likely to present with bone and joint infection (50z vs. 0z; p ＜ 0.0001), skin infections (31z Among the 16 patients in the case group, 11 underwent lumbar puncture to rule out cryptococcal meningitis. Three patients were diagnosed with cryptococcal meningitis; only 1 presented with a headache and stiff neck, while the other 2 presented with multiple sites of cryptococcal infection (1 had osteomyelitis of the tibia, a septic elbow joint, and a subcutaneous abscess, while the other had a skin ulcer with positive blood culture). The diagnosis in these 2 patients was made by following positive culture testing of the CSF. The CSF cryptococcal antigen (Ag) tests were negative, and the CSF analyses were normal (i.e., normal protein, glucose, and white blood cell counts).
Bone and joint infections were the most common presentation (n ＝ 8; 50z) in the case group patients, while there were none among the HIV-infected patients. Six patients in the case group had multiple bone and joint infections. The most common sites of osteomyelitis were the tibia (n ＝ 3) and lumbar spine with spondylitis (n ＝ 3). Other sites of osteomyelitis included 1 each in the zygoma, clavicle, and ulnar bone. The elbow joint was the most common site of arthritis in 4 cases, followed by 1 in the sternoclavicular joint and 1 in the shoulder joint.
Five patients had cryptococcal skin manifestation, and 3 of them had skin ulcer(s) over the infected bone, while 2 presented with subcutaneous abscesses. One HIV-infected patient presented with umbilicated skin nodules. Four of the cases presented with pneumonia, and 1 had a pleural effusion that tested positive following culture. Table 3 shows the characteristics of cryptococcosis in the 16 patients with non-HIV-infected disseminated NTM infection, including the date of diagnosis, the date of blood collection for IFN-g Ab testing, and the respective antibody titers. The IFN-g Ab titer ranged from 1:5,000 to 1:1,600,000. All of the 5 healthy controls tested negative for IFN-g Ab (titer ＜1:100) (data not shown).
The treatment and outcomes of cryptococcosis between the case and control groups are summarized in Table 4 . The most common induction regimen in both groups was intravenous amphotericin B deoxycholate, followed by intravenous amphotericin B deoxycholate plus fluconazole for 2 weeks. The majority of patients in both groups received a consolidation regimen with oral fluconazole (400 mg/day). Some received oral itraconazole (400 mg/day). After completing treatment, all HIV-infected patients received oral fluconazole or itraconazole (200 mg/day) for secondary prophylaxis, but none of the patients in the case group received this treatment. Compared to the control patients, the patents in the case group had a longer median hospitalization (30 vs. 15 days; p ＜ 0.0001) and treatment duration (31.3 vs. 11.9 weeks; p ＝ 0.005).
Outcome data were only available for 24 HIV-infected patients; as 5 were referred to a local hospital, 2 were lost to follow-up, and 1 had no data available. The respective mortality rates of the case and control groups were 12.5z and 29.2z ( p ＝ 0.27), respectively. Among the survivors, 0 and 3 (17.6z) patients in the case and control groups had clinical recurrence of cryptococcosis, respectively.
DISCUSSION
We reported a large number of non-HIV-infected patients with disseminated NTM from Thailand (2), the majority of whom presented with NTM lymphadenitis. They were also co-infected with many intracellular opportunistic infections, including cryptococcosis. We enrolled these patients into a study of adult onset immunodeficiency and found that the majority (88z) tested positive for IFN-g Ab (3). Among the 45 patients with other opportunistic infections with or without NTM infection, 43 (96z) tested positive for IFN-g Ab. All of these 43 patients had other opportunistic infection(s) and NTM. Of the 2 patients without IFN-g Ab, 1 had neutralizing anti-granulocyte macrophage colony-stimulating factor (GM-CSF) autoantibodies with disseminated cryptococcosis and pulmonary tuberculosis, and the other had cryptococcal meningitis alone (3). We thus infer that all of the patients coinfected with NTM and cryptococcosis in the present study had IFN-g Ab.
Cryptococcosis is a concerning opportunistic fungal infection, particularly among HIV-infected patients (5). Cryptococcosis is also seen in non-HIV-infected individuals, including transplant recipients, patients receiving immunosuppressive agents, and a heterogeneous group of patients with underlying disorders (e.g., organ failure syndromes, innate immunologic diseases, variable immunodeficiency, hematologic disorders, and even in phenotypically normal individuals) (6) . According to the results of the present study, IFN-g Ab should also be considered one of the predisposing factors underlying the development of cryptococcosis. Non-HIV infected individuals without a clear risk factor for cryptococcosis should be evaluated for IFN-g Ab, and if they test positive they should undergo assessment for concomitant opportunistic infections.
To our knowledge, this is the first single-site series of cryptococcosis in disseminated NTM-infected patients with IFN-g Ab. We observed significant differences in clinical features between the 2 groups. The IFN-g Ab positive patients exhibited more bone, joint, skin, and pulmonary involvement but had a lower incidence of meningitis compared to the HIV-infected patients. They were also less likely to test positive for serum cryptococcal Ag. These findings indicate that immunosuppression in the IFN-g Ab group is more subtle than in the HIV-infected group. Organ involvement in cryptococcosis was determined by assessing the underlying immune status. The organism is trophic to the CNS, and the majority of infections result in meningitis. CNS infection was more common among HIV-positive patients compared to organ transplant recipients and non-HIV, non-transplant patients, while pulmonary infection was less common among HIV-positive patients (6, 8) . The skeletal involvement in the IFN-g Ab group is very interesting, and a deeper understanding of the pathogenesis of cryptococcosis in this patient group should be further investigated.
Many patients in both groups had a history of concomitant opportunistic infections, which is indicative of a cell-mediated immune defect. The other opportunistic infections in these 2 groups were also different; herpes zoster infection (25z) and salmonellosis (25z) were common in the IFN-g Ab group, whereas tuberculosis (13z) and PCP (13z) were more common among HIV-infected patients. Cryptococcosis was the first presenting opportunistic infection in 66z of HIV-infected patients, but this was the case for only 25z of the IFN-g Ab group (p ＝ 0.0135).
We could not correlate the IFN-g Ab titer with the clinical presentation of cryptococcosis since IFN-g Ab testing only became available in 2011. Sampling and diagnosis of cryptococcosis were not performed within the same period. For those recently diagnosed and whose sera was taken close to their diagnoses (i.e., case no. 6-10), most had an IFN-g Ab titer of 1:10,000. In our previous study, IFN-g Ab was rare (1/48, 2z) in the healthy control (3), and this is supported by a study in Chiang Mai, Thailand, in which 20 HIV-infected patients and 20 healthy control participants tested negative for IFN-g Ab (11) . Given that the 5 healthy controls in our study all tested negative for IFN-g Ab, we contend that all of the HIV-infected patients with cryptococcosis in our study were negative for IFN-g Ab.
The choice of treatment for cryptococcosis depends on the immune status of the host and the site of infection. Amphotericin B plus flucytosine followed by fluconazole is preferred for CNS infection and for severe symptoms (12) . However, flucytosine is not available in Thailand, so most of the patients received either amphotericin B deoxycholate alone or with fluconazole. Patients in the IFN-g Ab group had a longer hospitalization period for treatment of cryptococcosis compared to those in the HIV-infected group. The IFN-g Ab group also received longer treatment with an oral azole as most patients had bone and joint infections. The severity of disease was modest, and the majority of patients (87.5z) were cured with no relapse. Only 2 patients died, 1 from severe cryptococcal meningitis and the other from septicemic melioidosis. Notwithstanding, we could not demonstrate a significant difference in the mortality rate between the 2 groups (12.5z vs. 29.2z; p ＝ 0.27).
It is currently understood that, HIV-infected patients have more severe immunosuppression due to CD4 Tcell depletion, which makes them susceptible to many opportunistic infections (OIs). The CD4 cell count can be used to predict the type of OIs; tuberculosis, PCP, and cryptococcosis are the most common OIs in Thailand (13) . The clinical course of these OIs was profound even with specific treatment. While IFN-g Ab positive patients have less severe disease, NTM is the most common OI in this patient group (3), and their clinical course is more protracted. The difference in immune defects, such as Mendelian susceptibility to mycobacterial disease, which consists of 9 genetic defects (IFNGR1, IFNGR2, STAT1, IL12B, IL1RB1, ISG15, IRF8, NEMO, and CYBB), have been reported to confer susceptibility to disseminated NTM but variable susceptibility to other intracellular opportunistic infections (4) . Levels of IFN-g Ab might be used to predict the type and number of OIs in these patients, but this needs further investigation.
The present study had a number of limitations. First, despite having collected data over many years, there were a small number of non-HIV-infected patients with cryptococcosis with disseminated NTM infection because of the rarity of the disease. Since patients with cryptococcosis who were diagnosed and treated more recently may have had better outcomes due to recent improvements in diagnosis and treatment options, we performed case-control matching (by time of admission nearest to the index case). Consequently, there was no difference in outcomes between the 2 groups. Second, the sera were not available for IFN-g Ab testing for some of the non-HIV-infected patients with disseminated NTM infection, especially for those seen in the earlier years of this study. Third, some data were missing due to the retrospective nature of this study. Fourth, strain of Cryptococcus was not identified, which might have had an impact on clinical manifestations and outcomes. This is the largest study of cryptococcosis in patients with disseminated NTM infection who tested positive for IFN-g Ab. The clinical manifestations of cryptococcosis were different in this group compared to those of HIV-infected patients, as they presented with more bone and joint infections, pulmonary involvement, and a lower incidence of meningitis. Recognizing the clinical features of such patients may improve the diagnosis and the timeliness of treatment.
